{'fraction_non_alphanumeric': 0.036464088397790057, 'fraction_numerical': 0.009944751381215469, 'mean_word_length': 6.306451612903226, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Prolonged agammaglobulinemia despite unaltered B-cell lymphopoiesis after peritransplant-rituximab administration in a child.

Prolonged Agammaglobulinemia Despite Unaltered B-Cell Lymphopoiesis After Peritransplant-Rituximab Administration in a Child With the following report, we aim to increase the awareness of severe alteration of B-cell maturation leading to agammaglobulinemia in patients who received anti-CD20 therapy after transplantation. A 18-month-old child received an allogeneic hematopoietic-stem cell transplantation (HSCT) from a 9/10 human leukocyte antigen-matched unrelated donor, as therapy for juvenile myelomonocytic leukemia. He had previously received (i) hydroxyurea, low dose-aracytine, and VP16, (ii) aracytine and mitoxantrone, and (iii) aracytine and amsacrine. Conditioning regimen consisted of busulfancyclophosphamide, melphalan, and antithymocyte globulin. The number of